Related Experiment Video

Updated: Jul 12, 2026

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?

Scott M Grundy1

  • 1Center for Human Nutrition, Department of Clinical Nutrition, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9052, USA. scott.grundy@utsouthwestern.edu

The American Journal of Medicine
|October 2, 2007
PubMed

Insights

Risk assessment algorithms help classify cardiovascular and metabolic risk. The metabolic syndrome increases risk, necessitating intensive therapy and lifestyle changes for all patients.

Area of Science:

  • Cardiology
  • Metabolic Disease
  • Preventive Medicine

Background:

  • Risk assessment algorithms, like the National Cholesterol Education Program's Adult Treatment Panel III (ATP III), aid in stratifying patient risk for cardiovascular and metabolic issues.
  • The metabolic syndrome, characterized by a cluster of risk factors, significantly elevates the risk for diabetes mellitus and atherosclerotic cardiovascular disease.

Purpose of the Study:

  • To evaluate the utility of risk assessment algorithms in guiding therapeutic interventions for cardiovascular and metabolic diseases.
  • To highlight the additional risk conferred by the metabolic syndrome across different risk strata.

Main Methods:

  • Utilizing established risk assessment algorithms (e.g., ATP III) to categorize patient risk levels.
  • Analyzing the impact of metabolic syndrome on overall cardiovascular and diabetes risk.
  • Reviewing current guidelines for pharmacotherapy and lifestyle modifications based on risk stratification.

Main Results:

  • Risk assessment algorithms effectively classify patients, dictating the intensity of therapeutic interventions.
  • Metabolic syndrome presence amplifies cardiovascular and diabetes risk at all assessed levels.
  • Both pharmacotherapy and lifestyle interventions are crucial components of management.

Conclusions:

  • Risk stratification tools are essential for personalized cardiovascular and metabolic disease management.
  • Addressing metabolic syndrome is critical for mitigating associated risks.
  • A combination of pharmacotherapy and lifestyle modifications ensures comprehensive patient care across all risk categories.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...